To vaccinate or not: hepatitis a seroprevalence in institutionalized patients with intellectual disability
Gastroenterology and Hepatology from Bed to Bench,
Vol. 17 No. 4 (2024),
2 December 2024
https://doi.org/10.22037/ghfbb.v17i4.2984
Abstract
Aim: Our goal was to assess the need for vaccination and preventive measures in this vulnerable population.
Background: HAV is the most common form of acute viral hepatitis, transmitted primarily via fecal-oral route. Therefore, poor hygiene and close contact among institutionalized people are associated with higher HAV infection prevalence. We sought to determine the seroprevalence of anti-HAV antibodies among institutionalized individuals with intellectual impairments in light of Iran's falling trend in HAV antibody prevalence.
Methods: In this cross-sectional study, we evaluated the seroprevalence of total and IgM anti-HAV antibodies of 254 institutionalized people with intellectual disabilities. Total and IgM anti-HAV antibodies of the blood samples of these people were determined by ELISA method.
Results: The seroprevalence of total and IgM anti-HAV antibodies among institutionalized people with intellectual disability were 15.4% and 0.4% respectively. In comparison to other institutionalized patients, individuals who were elderly and had spent more time in the institutions exhibited a higher prevalence of anti-HAV antibodies (p-values= 0.011 and <0.001, for example).
Conclusion: Based on our study, intellectually disabled people have a low prevalence of anti-HAV antibodies, which increases with age and the duration of institutionalization. Therefore, vaccination is necessary to prevent serious infection in these people.
- Hepatitis
- HAV
- Seroprevalence
- intellectual disability
- institutionalized
How to Cite
References
Jain P, Prakash S, Gupta S, Singh KP, Shrivastava S, Singh DD, et al. Prevalence of hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus as causes of acute viral hepatitis in North India: A hospital based study. Indian J Med Microbiol 2013;31:261-5.
Organization WH. Hepatitis A vaccines: WHO position paper. Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire 2000;75:38-44.
Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol 2017;0168-8278:32278-X.
Abutaleb A, Kottilil S. Hepatitis A: epidemiology, natural history, unusual clinical manifestations, and prevention. Gastroenterol Clin North Am 2020;49:191-9.
Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A. Cold Spring Harb Perspect Med 2018;8:031708.
Koff RS. Hepatitis a. Lancet 1998;351:1643-9.
Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. J Hepatol 1993;18:11-4.
Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol 2012;4:68-73.
Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006;28:101-11.
Szmuness W, Purcell RH, Dienstag JL, Stevens CE. Antibody to hepatitis A antigen in institutionalized mentally retarded patients. Jama 1977;237:1702-5.
Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population--a viral marker study. Ann Acad Med Singap 1980;9:144-8.
Farajzadegan Z, Hoseini SG, Kelishadi R, Jamshidi F, Nokhodian Z, Noori R, et al. Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran. J Res Med Sci 2014;19:56-63.
Izadi M, Esfahani AA, Hassannia H, Jafari NJ, Najarkolaei FR, Rezaee-Zavareh MS. Seroprevalence of hepatitis A virus among Iranian soldiers. Gastroenterol Hepatol Bed Bench 2016;9:100-4.
Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med 2013;35:121-6.
Asaei S, Ziyaeyan M, Moeini M, Jamalidoust M, Behzadi MA. Seroprevalence of hepatitis A and E virus infections among healthy population in shiraz, southern Iran. Jundishapur J Microbiol 2015;8:19311.
Alian S, Ajami A, Ghasemian R, Yadegarinia D. Age-specific seroprevalence of hepatitis a in sari, northern Islamic Republic of Iran. East Mediterr Health J 2011;17:754-8.
Ataei B, Nokhodian Z, Ali Javadi A, Kasaeyan N, Farajzadegan Z, Shoaei P, Adibi P. Seroepidemiology of hepatitis a virus infections in over 6-years population in Isfahan–Iran: A community-based study. J Isfahan Med Sch 2007;25:53-46
Bakhshipour A, Sargolzaie N, Rafaiee R. Status of immunity against the hepatitis A virus in healthy population: a report from southeastern Iran. Arch Clin Infect Dis 2021;16:0-0.
Bayani M, Hasanjani Roushan MR, Javanian M, Kalantari N, Hajitabar M. Hepatitis A antibody seroprevalence among students of Babol university of medical sciences; Babol, Iran. J Babol Univ Med Sci 2014;16:49-53.
Behzadi MA, Leyva-Grado VH, Namayandeh M, Ziyaeyan A, Feyznezhad R, Dorzaban H, et al. Seroprevalence of viral hepatitis A, B, C, D and e viruses in the Hormozgan province southern Iran. BMC Infect Dis 2019;19.
Honarvar B, Zahedroozegar MH, Asmarian N, Zahedroozegar A, Saber K, Lankarani KB. Hepatitis A chronic immunity: a population-based seroprevalence study in Fars province, southern Iran. Hepat Mon 2021;21.
Mahavar N, Fereidouni M, Ziaee M. Seroprevalence of hepatitis a virus among healthy individuals in Birjand, Eastern Region of Iran. Hepat Mon 2018;18:0-0.
Vitral CL, Gaspar AMC, Souto FJD. Epidemiological pattern and mortality rates for hepatitis A in Brazil, 1980-2002: a review. Mem Inst Oswaldo Cruz 2006;101:119-27.
Ansaldi F, Bruzzone B, Rota MC, Bella A, Ciofi degli Atti M, Durando P, et al. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol 2008;23:45-53.
Lankarani KB, Honarvar B, Vardanjani HM, Kharmandar A, Gouya MM, Zahraei SM, et al. Immunity to Hepatitis-A virus: A nationwide population-based seroprevalence study from Iran. Vaccine 2020;38:7100-7.
Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 2003;21:2224-33.
Gil A, González A, Dal-Ré R, Dominguez V, Ortega P, Barrio JL, Aguilar L. Prevalence of hepatitis A in an institution for the mentally retarded in an intermediate endemicity area: Influence of age length of institutionalizatian. J Infect 1999;38:120-3.
Woodruff BA, Vazquez E. Prevalence of hepatitis virus infections in an institution for persons with developmental disabilities. Am J Ment Retard 2002;107:278-92.
Sayers G, Dooley S, Staines A, Lane J, Thornton L, Staines M, et al. Hepatitis A antibody prevalence among people with an intellectual disability in Ireland. Eurosurveillance 2007;12:5-6.
Ramezani A, Aghasadeghi MR, Mamishi S, Sabeti S, Bidari-Zerehpoosh F, Banifazl M, et al. Seroprevalence of hepatitis a among children and young adults residing in Tehran, Iran: Implication for HAV vaccination. Hepat Mon 2018;18.
- Abstract Viewed: 155 times
- PDF Downloaded: 5 times